REVIEW

Open Access

Hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis



Dominic Cooper¹, Rajneesh Kaur, Femi E. Ayeni^{2,3*}, Guy D. Eslick³ and Senarath Edirimanne^{2,3}

Abstract

Background The incidence of hypothyroidism following hemithyroidectomy and risk factors associated with its occurrence are not completely understood. This systematic review investigated the incidence and risk factors for hypothyroidism, thyroxine supplementation following hemithyroidectomy as well as the course of post-operative hypothyroidism, including the time to hypothyroidism and incidence of transient hypothyroidism.

Methods Searches were conducted in MEDLINE, EMBASE, Scopus, and Cochrane library for studies reporting the incidence of hypothyroidism or thyroxine supplementation following hemithyroidectomy.

Results Sixty-six studies were eligible for inclusion: 36 reported risk factors, and 27 reported post-operative course of hypothyroidism. Median follow-up was 25.2 months. The pooled incidence of hypothyroidism was 29% (95% Cl, 25-34%; P<0.001). Transient hypothyroidism occurred in 34% of patients (95% Cl, 21-47%; P<0.001). The pooled incidence of thyroxine supplementation was 23% (95% Cl, 19-27%; P<0.001), overt hypothyroidism 4% (95% Cl, 2-6%, P<0.001). Risk factors for development of hypothyroidism included pre-operative thyroid stimulating hormone (TSH) (WMD, 0.87; 95% Cl, 0.75-0.98; P<0.001), TSH \ge 2 mIU/L (RR, 2.87; 95% Cl, 2.43-3.40; P<0.001), female sex (RR, 1.19; 95% Cl, 1.08-1.32; P=0.007), age (WMD, 2.29; 95% Cl, 1.20-3.38; P<0.001), right sided hemithyroidectomy (RR, 1.35; 95% Cl, 1.10-1.65, P=0.003), the presence of autoantibodies anti-TPO (RR, 1.92; 95% Cl, 1.49-2.48; P<0.001), anti-Tg (RR, 1.53; 95% Cl, 1.40-1.88; P<0.001), and Hashimoto's thyroiditis (RR, 2.05; 95% Cl, 1.57-2.68; P=0.001).

Conclusion A significant number of patients will develop hypothyroidism or require thyroxine following hemithyroidectomy. An awareness of patient risk factors and postoperative thyroid function course will assist in counselling patients on their risk profile and guiding management.

Keywords Hypothyroid, Hypothyroidism, Hemithyroidectomy, Thyroid lobectomy, Thyroxine

Introduction

Hemithyroidectomy is commonly used for the management of benign unilateral thyroid conditions and low risk differentiated malignancy. In most cases the remaining

*Correspondence:

² Nepean Institute of Academic Surgery, The University of Sydney School of Medicine, 62 Derby St, Kingswood, Sydney, NSW 2750, Australia ³ The University of Sydney School of Medicine, Nepean Clinical School, Sydney, Australia thyroid gland can compensate and maintain normal thyroid function in the absence of one thyroid lobe, but a minority of patients will develop hypothyroidism following surgery [1]. Hypothyroidism is readily managed with thyroxine treatment. Thyroxine therapy though have been shown to reduce the risk of thyroid nodules by inhibiting nodule growth [2], but it is also associated with adverse cardiovascular, and musculoskeletal effects [3, 4], and demands regular monitoring and follow up, meaning it represents an important complication for many patients. The incidence of hypothyroidism following hemithyroidectomy shows heterogeneity in the literature, with reported incidence ranging from 9.5%



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Femi E. Ayeni

femi.ayeni@sydney.edu.au

¹ The University of Sydney School of Medicine, Sydney, Australia

to 64.2% [5, 6]. This may be explained by many factors, such as regional differences in iodine status and baseline thyroid function, definition of hypothyroidism, sample size, follow up protocol and duration, and patient characteristics such as age, pre-operative thyroid stimulating hormone (TSH) and sex [7–9]. Some of these factors can be assessed in the pre-operative period to advise patients on their individualised risk of hypothyroidism, which can improve decision making and thus help in the identification of high-risk patients for closer follow up and assessment.

A meta-analysis was published in November 2020 on hypothyroidism after hemithyroidectomy [10]. That study found the prevalence of hypothyroidism to be 29.9%, as well as several risk factors for its development.

Our report aimed to build on the previous analysis in several regards. Firstly, that study did not explore the risk of overt hypothyroidism. Overt hypothyroidism reflects a progression from biochemical hypothyroidism and has significant health consequences that necessitates treatment with thyroxine [11]. Further, our study explored several previously unreported risk factors, including the risk of older age and autoantibodies anti-TPO and anti-Tg.

Finally, the postoperative course of thyroid function remains unclear. Thyroid function following hemithyroidectomy has been observed to decline in the short term (≤ 6 months) before subsequently recovering [12], with many patients attracting only a transient diagnosis of hypothyroidism [13–15]. In the absence of suitable follow up, this may lead to overdiagnosis of hypothyroid-ism in the short term after surgery and overtreatment of potentially self-resolving cases of hypothyroidism.

The aim of this study was to develop an updated systematic review and meta-analysis of the literature to determine the incidence of hypothyroidism after hemithyroidectomy, analyse risk factors associated with the development of hypothyroidism, and clarify the natural course of post-surgical hypothyroidism, including the time to hypothyroidism, post-operative TSH recovery, as well as the incidence of transient hypothyroidism to improve clinical decision making.

Methods

Literature search strategy

Literature searches were conducted through MEDLINE, EMBASE, Scopus, and Cochrane library databases. The search terms included "hemithyroidectomy" OR "hemi thyroidectomy" OR "hemi-thyroidectomy" OR "lobectomy" OR "thyroid lobectomy" AND "hypothyroid*" OR "levothyroxine" OR "thyroxine" OR "thyroid hormone". The search was limited to the English language. There was no limit on publication date. The search was current until the 18th of May 2023. Reference lists of included papers were reviewed for any further relevant papers.

Eligibility criteria

Studies reporting hypothyroidism or thyroxine supplementation following hemithyroidectomy or thyroid lobectomy were eligible for inclusion. Where studies reported on thyroxine supplementation and not hypothyroidism it was assumed that the indication for thyroxine initiation was hypothyroidism unless otherwise specified. Studies that empirically treated with thyroxine supplementation were excluded. Where studies included multiple surgical types, such as subtotal, partial, or total thyroidectomies, only the hemithyroidectomy group was included. No restriction was placed on the indication for surgery, with both benign and malignant indications included. Papers that did not explicitly include preoperative thyroid status were included. Where multiple studies used overlapping data, the first publication was used. Only full text articles were considered for inclusion. Meeting abstracts and unpublished data were excluded. Only papers in the English language were included.

Study selection and data extraction

All papers were screened by two reviewers (DC and SE) by title, then abstract and full text. The included papers were then analysed, with data extracted by a single reviewer (DC). The data was extracted into a predefined spreadsheet. Data extracted included (i) study characteristics (author, year of publication, country of origin), (ii) cohort characteristics (age, sex, cohort number), (iii) surgical information (indication for surgery, side of hemithvroidectomy, benign or malignant pathology, thyroid comorbidities), (iv) biochemistry (pre-operative TSH, thyroid autoantibodies), and (v) postoperative follow up (hypothyroid incidence, transient hypothyroid incidence, time of hypothyroid diagnosis, follow up duration, protocol for thyroid status measurements, and postoperative thyroid hormone supplementation incidence and indication).

Quality assessment

The studies were assessed using a modified Newcastle Ottawa Scale for cohort studies (Sup. Table 1). The assessment was carried out independently by one primary reviewer (DC) and reviewed by a second independent reviewer (SE). Differences were resolved by unanimous agreement.

Statistical analysis

A meta-analysis of the pooled data was performed using Review Manager 5.4 [16]. Dichotomous variables were reported using a risk ratio (RR), and continuous variables by a weighted mean difference (WMD). Statistical significance was defined as P < 0.05. The Mantel-Haenszel random effects model was used following consideration of the study heterogeneity. Heterogeneity was assessed using the Chi² test and reported with the I² statistic, with I² <50%, 50-75%, >75% used to indicate low, moderate, and high degrees of heterogeneity respectively. Forest plots were constructed for each outcome of interest. Funnel plot symmetry was used to assess publication bias.

Results

Literature search

The search protocol produced 1262 non duplicate articles. Following screening by title and abstract, 92 papers remained. A further 26 papers were excluded on full text review for the following reasons: non-English language (n=3), reported incidence of hypothyroidism or thyroxine supplementation (n=3), no full text available (n=5), empirical thyroxine treatment (n=8), conference article or poster presentation (n=5), duplicate patient cohorts (n=2). 66 articles were included in the review. The PRISMA flowchart is represented in Fig. 1

Quality Assessment results

The 66 cohort studies were assessed using a modified Newcastle Ottawa scale for cohort studies (Sup.Table 1). Of these, 42 studies scored \geq 5/6 and were considered high quality.

Study characteristics

The study characteristics are outlined in Table 1. Sixty-six studies were included with a total of 13,546 patients [5, 6, 9, 13, 15, 17–77]. Study sizes ranged from 14 to 1240 participants. Publication years ranged from 1986 to 2022. The postoperative incidence of hypothyroidism ranged from 0 to 66.2%. The mean age ranged from 13.65 to 53 years, with a median of 47.7 years. Females accounted for the majority of patients in sixty-five studies.

The duration of follow up varied between 6 months and 168 months, with a median of 25.2 months. There was a variability in terms of the post-operative thyroid function measurement protocols. In some instances, the thyroid function was measured only once at 6 weeks postoperatively, while in others it was measured at 3, 6, and 12 months, with regular 12 monthly tests thereafter. In majority of the studies, hypothyroidism was defined as an elevation in TSH above the upper limit of normal, ranging from 3.74 to 6 μ IU/mL.

Incidence of hypothyroidism

The weighted pooled incidence of hypothyroidism following hemithyroidectomy was 29% (95% CI, 25-34%; P<0.001) (Fig. 2). The weighted pooled incidence of thyroxine supplementation following hemithyroidectomy was 23% (95% CI, 19-27%; P<0.001) (Fig. 3). The weighted pooled incidence of overt hypothyroidism was 4% (95% CI, 2-6%, P<0.001) (Fig. 4). Each of these three assessments showed a high degree of heterogeneity (1² > 75%). Funnel plots for these studies qualitatively show asymmetry which may suggest publication bias (Sup. Figures 1-3).

Risk factors for hypothyroidism

Pre-operative TSH was higher in post-operatively hypothyroid patients. The risk ratio for patients with high normal TSH ($\geq 2 \text{ mIU/L}$) was 2.87 (95% CI, 2.43-3.40; *P*<0.001) (Fig. 5), with a preoperative TSH WMD of 0.87 (95% CI, 0.75-0.98; *P*<0.001) (Sup. Figure 4).

Older patients are at greater risk of hypothyroidism. Ages ranged between 39.42-58.1 years in the hypothyroid group in adult studies, and 36.36-50.95 years in euthyroid populations, with a WMD of 2.29 (95% CI, 1.20-3.38; P<0.001) (Fig. 6).

Females were at greater risk of developing hypothyroidism, with a pooled RR of 1.19 (95% CI, 1.08-1.32; P=0.007) (Fig. 7).

Patients with concomitant histopathological Hashimoto's thyroiditis displayed the greatest single risk in this study for post-hemithyroidectomy hypothyroidism, with a pooled RR of 2.05 (95% CI, 1.57-2.68; P=0.001 (Fig. 8). Auto-antibodies are commonly associated with thyroiditis. Both anti-TPO antibody and anti-Tg antibody were associated with an increased risk for hypothyroidism, with a weighted pooled RR of 1.92 (95% CI, 1.49-2.48; P<0.001) and 1.53 (95% CI, 1.40-1.88; P<0.001) respectively (Sup. Figures 5, 6).

The side of the hemithyroidectomy in this study was also associated with an increased risk of hypothyroidism, with right sided hemithyroidectomies associated with a weighted pooled RR of 1.35 (95% CI, 1.10-1.65, P=0.003) (Sup. Figure 7).

A malignant surgical indication, family history of thyroid dysfunction, body mass index (BMI), and remnant thyroid volume were not associated with post-operative hypothyroidism (Sup. Figures 8-11).

Heterogeneity was very high ($I^2 > 75\%$) in the Hashimoto's thyroiditis group, moderately high ($I^2 = 50-75\%$) in the age, TSH, anti-TPO and anti-Tg groups, and low ($I^2 < 50\%$) for female sex, TSH ≥ 2 mIU/L and side of hemithyroidectomy groups.

Funnel plots for age, female sex, Hashimoto's thyroiditis, pre-operative TSH, malignant pathology and side of hemithyroidectomy qualitatively show symmetry (Sup. Figures 12-17). Funnel plots for TSH \geq 2, anti-TPO and anti-Tg qualitatively show asymmetry which may suggest publication bias (Sup. Figures 18-20).

Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration, <i>months</i> ,	Definition of hypothyroidism	Interval to hypothyroidism	Thyroid function follow-up protocol
					(range)		from intervention, months	
Abraham, C. R., et al. (2022) [17]	170	63 (37.1)	47.0 (14.1)	140 (82.4)	22.7	TSH > 4.5 mIU/L	NR	NR
Ahn, D, et al. (2016) [7]	405	226 (55.8)	47.4	345 (85.2)	56.4 (12-105)	TSH > 4.5 mU/L	ú.	TF measured 1–3 months after surgery. If normal, follow-up thyroid function measurements were performed every 6–12 months. If subclini- cal hypothyroidism was identified, thyroid function measure- ment was per- formed at 3 months and repeated every 3–6 months
Akkari, M., et al. (2014) [18]	14	3 (21.4)	NR	NR	45	NR	5.6	NR
Alsaleh, N., et al. (2021) [19]	38	13 (34.2)	42 (14)	25 (65.8)	24	TSH > 4.8 µIU/mL	NR	TFT measured at least 6 weeks postopera- tively
Al-Shalhoub, A. K. and S. Al-Dhahri (2017) [20]	ω	37 (44.6)	α m	67 (80.7)	2	T5H > 5 mlU/L	ц	The first postopera- tive thyroid function follow-up test was performed at dif- ferent time points; whereas 40 patients (48.2%) had their first postoperative thyroid function test at 3 months, 6 patients (7.2%) at 9 months, ine patients (10.8%) at 12 months and two patients (2.4%) at 18 months
Antunes, C. M. and A. Taveira-Gomes (2013) [21]	109	40 (36.7)	48.68 (14.93)	R	60	NR	NR	NR

Article	Patient Number	Patient Number Hypothyroid, No. (%)	Age, <i>years,</i> mean (SD)	Sex, female, No. (%)	Follow up duration, <i>months</i> , (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
Attaallah, W., et al. (2015) [22]	259	56 (21.6)	43.1 (12.2)	195 (75.3)	31 (6-126)	NR	NR	NR
Balentine, C. J., et al. (2013) [23]	17	8 (47.1)	52.8 (16.5)	15 (88.2)	NR	NR	NR	NR
Baran, J. A., et al. (2021) [24]	110	31 (28.2)	14.9 (2.5)	94 (85.5)	12 (1-62)	TSH > 4.5 mlU/L	1.7	NR
Barczynski, M., et al. (2010) [25]	22	17 (23.6)	40.1 (10.2)	62 (86.1)	Q	٣	٣	All the patients were evaluated every 3 months during the first year and every 12 months for the following years up to comple- tion of the planned 60-month follow-up. The biochemical evaluation consisted of serum values of FI3, FI4, and TSH
Bauer, P. S., et al. (2013) [26]	420	79 (18.8)	50.7	327 (77.9)	46.1	NR	NR	NR
Beisa, V., et al. (2015) [27]	109	20 (18.4)	NR	91 (83.5)	12	TSH > 4 mlU/L	R	Postoperative TSH and LT3 and LT4 tests were performed 2, 6, and 12 months after the surgery
Beisa, V., et al. (2011) [28]	216	48 (22.2)	ХК	194 (89.8)	20	TSH > 4 mlU/L	NR	A postoperative TSH test was performed 2, 6 and 20 months after the surgery
Berglund, J., et al. (1998) [29]	26	(0) 0	48.5	20 (76.9)	12	R	ХХ	Serum concentra- tions of thyroxine, triiodothyronine (T3) and thyroid stimulating hormone (T5H) were measured preoperatively and 1, 3, 6, 12 months post- operatively

Table 1 (continued)	d)							
Article	Patient Number	Hypothyroid, No. (%)	Age, <i>year</i> s, mean (SD)	Sex, female, No. (%)	Follow up duration <i>, months,</i> (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
Buehler, L. A., et al. (2021) [13]	210	96 (45.7)	51.1 (15.3)	NR	50 (12-59.9)	TSH > 4.2 mIU/L	NR	NR
Cao, Z., et al. (2022) [30]	378	110 (29.1)	٣	280 (74.1)	٣	TSH > 4.34 µlU/ml	3.47	During the followup period, patients underwent thyroid function assess- ments at 1, 3, 6, and 12 months postoperatively, then every six months after that. However, when patients com- plained the clinical symptoms related to thyroid dysfunction or had suspicious TFT results, TFTs were per- formed at any time
Chen, J., et al. (2019) [31]	43	11 (25.6)	13.65 (3.04)	34 (79.1)	28	TSH > 3.9 µIU/mL	4.1	TSH measured at least 6 weeks postopera- tively
Cheung, P., et al. (1986) [32]	103	13 (12.6)	39	80 (77.7)	36	NR	R	TSH and FT4 measured at 6 months, 1, 2, and 3 years postop- eratively
Chidambarana- than, N., et al. (2021) [33])	128	26 (20.3)	36.5	103 (80.5)	27.5 (0-96)	NR	6.5	The first TFT was done on most occa- sions at around 3–6 months, and subse- quently thereafter, it was repeated every 6–12 months
Cho, J. S., et al. (2011) [34]	123	26 (21.2)	R	87 (70.7)	35.7 (06-80)	TSH > 6 mU/L	Ж	Patients were fol- lowed up at 3 to 6 months intervals during the first two postoperative years, and annually there- after

Table 1 (continued)])							
Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration, <i>months</i> , (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
Cho, M. J., et al. (2021) [35]	29	6 (20.7)	40 (2)	23 (79.3)	12	TSH > 4.1 µIU/ml	ĸ	T5H was measured before surgery, and 3 months and 1 year after surgery
Chong, S. S., et al. (2019) [36]	101	23 (22.8)	48	83 (82.2)	29.3	TSH > 4.2 µIU/mL	NR	TSH, total T4, T3 were measured 2 months after surgery
Chotigavanich, C., et al. (2016) [37]	100	27 (27)	43.6 (12.2)	93 (93)	NR	TSH > 4 µIU/mL	NR	TFT was performed six weeks after surgery
Chu, K. K. M. and B. H. H. Lang (2012) [38]	263	38 (14.5)	ХX	204 (77.6)	21 (3–62)	TSH > 5.5 mlU/L	m	Postoperative serum TSH was monitored regularly at 2 weeks, 3 months, 6 months, and yearly after sur- gery until the patient was lost to follow-up evaluation
De Carlucci Jr, D., et al. (2008) [39]	186	61 (32.8)	45 (14)	163 (87.6)	29 (6-108)	TSH > 5.5 mIU/L	NR	TSH and fT4 measured postoperatively, 4 to 8 weeks after surgery
Dou, Y., et al. (2020) 190 [8]	190	77 (40.5)	40.4 (10.4)	140 (73.7)	36 (20-36)	TSH > 5.92 mIU/L	ĸ	TFT in the first month, every three months during the first postoperative year, and then every six months dur- ing the second and third years
Ergul, Z., et al. (2014) [40]	50	8 (16)	423 (127)	36 (72)	25.2 (10-43)	TSH > 4.5 µlU/mL	Ř	Follow-up with thy- roid function tests on the first month and then once every three months, as well as ultrasonography controls once a year were performed postoperatively

Artle Reinthumber Myophyodi Mo. Gay parts mean Sev. femile M Performation frame Perfo	Table 1 (continued)	4)							
175 87 (49.7) 4.2.(12.2) 148 (84.6) 7.5 (1-1.2) NR 19 150 56 (37.3) NR 116 (77.3) 18 75H > 5 mU/L 117 25 (21.4) 49.6 98 (83.8) NR 75H > 5 mU/L 252 98 (38.9) NR 71H > 5 mU/L 75H > 5 mU/L 252 98 (38.9) NR 71H > 5 mU/L 75H > 4 0 5 mU/L 252 98 (38.9) NR 47 (18.7) 38.3 (-10.4) 75H > 4 0 5 mU/L 253 169 (66) 43.79 (10.92) 204 (79.7) 64.5 75H > 4 0 7 mU/L 254 8 (28.6) 49 22 (78.6) 22 2 75H > 4 mU/L 26 8 (28.6) 49 22 (78.6) 22 2 75H > 4 mU/L 28 8 (28.6) 49 115 (84.6) 22 2 NR 75H > 4 mU/L 28 8 (28.6) 49 115 (84.6) 232 7H > 47 mU/L 29 8 (28.6) NR 12 (84.6) 232 7H > 47 mU/L 20	Article	Patient Number		Age, <i>year</i> s, mean (SD)	Sex, female, No. (%)	Follow up duration, <i>months</i> , (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
IJ IJ<	Ha, T. K., et al. (2019) [41]	175	87 (49.7)	45.2 (12.2)	148 (84.6)	7.5 (1-12)	R	Ĕ	TFTs were performed routinely at 1, 3, 6, and 12 months after lobectomy
117 25 (214) 49.6 98 (638) NR T5H > 55 mU/L 252 98 (389) NR 47 (18.7) 38.3 (3-104) T5H > 405 mU/L 256 169 (66) 43.79 (10-22) 204 (79.7) 64.5 T5H > 407 mU/L 256 169 (66) 43.79 (10-22) 204 (79.7) 64.5 T5H > 47 mU/L 258 169 (66) 43.79 (10-22) 204 (79.7) 64.5 T5H > 47 mU/L 26 169 (66) 43.79 (10-22) 204 (79.7) 64.5 T5H > 47 mU/L 26 58 (42.7) 42.7 (11.7) 115 (84.6) 22.2 NR 27 58 82.86.6 12 22 (78.6) 12 27 150 442 NR 125 (83.3) 53.5 T5H > 47.8 mU/L	lto, M., et al. (2015) [42]	150	56 (37.3)	ЛК	116 (77.3)	8	TSH > 5 mlU/L	٣	Thyroid function tests were performed 1 month after surgery and every 3–6 months thereafter
252 98(389) NR 47(18.7) 38.3 (3-10.4) TSH > 405 mU/L 256 169(66) 43.79(10.92) 204(79.7) 64.5 TSH > 4.7 mU/L 136 58(42.7) 42.7 (11.7) 115 (84.6) 222 TSH > 4.4 mU/L 28 8(28.6) 49 22 (78.6) 12 NR 150 44(29.3) NR 125 (83.3) 53.5 TSH > 4.78 mU/L	Johner, A., et al. (2011) [12]	117	25 (21.4)	49.6	98 (83.8)	М	TSH > 5.5 mlU/L	٣	TSH at 6 weeks or 3 months, and 6 and 12 months postop- eratively. Followed 6 monthly or annually depending on cat- egory of TSH level
tal. 256 169 (66) 43.79 (10.20) 204 (79.7) 64.5 TSH > 4.7 mU/L etal. 136 58 (42.7) 42.7 (11.7) 115 (84.6) 22.2 TSH > 4 mU/L ital. 136 58 (42.7) 42.7 (11.7) 115 (84.6) 22.2 TSH > 4 mU/L ital. 138 58 (42.7) 42.7 (11.7) 115 (84.6) 22.2 TSH > 4 mU/L ital. 138 8 (28.6) 49 22 (78.6) 12 NR ital. 150 44(29.3) NR 125 (83.3) 53.5 TSH > 478 mU/L	Kim, C. J., et al. (2020) [14]	252	98 (38.9)	X	47 (18.7)	38.3 (3-104)	TSH > 4.05 mU/L	Ϋ́Ζ	TSH and fT4 levels were checked postoperatively at 1 week, 1-3 months, 6 months, and annually and/or biannually thereafter
et al. 136 58 (42.7) 42.7 (11.7) 115 (84.6) 22.2 TSH > 4 mU/L T.T. 28 8 (28.6) 49 22 (78.6) 12 NR (45] 15 49 22 (78.6) 12 NR et al. 150 44 (29.3) NR 125 (83.3) 53.5 TSH > 4.78 mU/L	Kim, S. Y., et al. (2020) [43]	256	169 (66)	43.79 (10.92)	204 (79.7)	64.5	TSH > 4.7 mIU/L	Ϋ́Ζ	TFT at the time of out- patient visit every 6 months for the 1st year, with an annual follow-up thereafter
T.T. 28 8 (28.6) 49 22 (78.6) 12 NR [45] 150 44 (29.3) NR 125 (83.3) 53.5 TSH > 4.78 mU/L	Koh, Y. W., et al. (2008) [44]	136	58 (42.7)	42.7 (11.7)	115 (84.6)	22.2	TSH > 4 mIU/L	NR	TSH and T4 at 1, 6 and 12 months
et al. 150 44 (29.3) NR 125 (83.3) 53.5 T5H > 4.78 mU/L	Kristensen, T. T., et al. (2014) [45]	28	8 (28.6)	49	22 (78.6)	12	NR	3.9	TSH and thyroid hormones at 1, 3, 6 and 12 months
	Lang, B. H., et al. (2017) [46]	150	44 (29.3)	Я	125 (83.3)	53.5	T5H > 4.78 mIU/L	3.2	Postoperative TSH and FT4 were checked at 1, 3, 6, and 12 months, then every 6 months thereafter

lable 1 (continued)								
Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration <i>, months,</i> (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>month</i> s	Thyroid function follow-up protocol
Lankarani, M., et al. (2008) [47]	45	8 (17.8)	٣	٣	12	٣	٣	During the first three months after surgery, all patients were visited monthly, then 2 monthly and then on a 3 monthly basis. In each visit FT of each patient was repeated and reg- stered
Latoo, M. A., et al. (2020) [48]	2	18 (36)	35.58 (10.226)	38 (76)	2	TSH > 4.5 mU/L	6. E	The first TFT measured 1 month after surgery. If normal, follow- up measurements of thyroid function were performed at 6 months and 12 months. If subclini- cal hypothyroidism was identified at any time during the fol- low-up period, thyroid function measure- ment was per- formed 3 months after that point and was repeated
Lee, D. Y., et al. (2015) [49]	276	65 (23.6)	49	196 (71)	28.8 (3.67-105)	NR	3.2	TSH levels at 1 week, 1 month, 4 months, 1 vear. and 2 vears
Lee, S. J., et al. (2021) [50]	353	193 (54.7)	46.4 (12.3)	258 (73.1)	31.4	TSH > 4.2 µIU/ml	5.5	TSH and fT4 levels were measured at 1 week, 1 month, and 3, 6, and 12 months, and after that at 6–12- month intervals
Lindblom, P., et al. (2001) [51]	37	8 (21.6)	44	33 (89.2)	NR	NR	NR	NR

Table 1 (continued)	d)							
Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration <i>, months,</i> (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
McHenry, C. R. and S. J. Slusarczyk (2000) [52]	71	25 (35.2)	ĸ	59 (83.1)	22 (1-86)	TSH > 3.59 µIU/mL	NR	NR
Meyer, C. D., et al. (2020) [53]	369	111 (30.1)	43.8 (12.3)	278 (75.3)	74.8 (0.43-160)	NR	NR	NR
Miller, F. R., et al. (2006) [54]	06	24 (26.7)	45	73 (81.1)	12.4 (3-24)	TSH > 6.0 mIU/L	6.6	TSH test at least 8 to 10 weeks after sur- gery and every 3 to 4 months subsequently
Moon, H. G., et al. (2008) [55]	101	37 (36.6)	47.5 (12.7)	76 (75.3)	12	R	ЛR	TFT at 2 months and every 2 to 3 months during the fol- low-up period
Morris, L., et al. (2013) [56]	8	45 (45.9)	52.5 (13.18)	74 (75.5)	11.6 (1.2-51.3)	N	7.86	TSH measured 4 to 8 weeks follow- ing thyroid lobectomy and then every 6 months during routine follow-up visits
Ng, P, et al. (2019) [15]	901	123 (13.7)	45.99 (13.24)	682 (75 <i>.</i> 7)	65 (3-180)	T5H > 4.5 µlU/mL	21	TSH measured at 6-8 weeks after thyroid surgery, and subse- quently at 6 months, 1 year, 2 years, and 5 years or at latest clinic visit
Noureldine, S. I., et al. (2013) [5]	105	10 (9.5)	48.4 (11.7)	99 (94.3)	ω	TSH > 3.74 μIU/mL	NR	TFT at 4 to 6 weeks

Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration <i>, months,</i> (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
Park, S, et al. (2017) [6]	335	215 (64.2)	47.9 (10.5)	266 (79.4)	56.2	TSH > 4.5 mlU/L	3.98	TSH and FT4 measured at 2 to 3 months after lobectomy. Euthyroid patients were monitored every 6 to 12 months thereafter. Once hypothyroidism was diagnosed, all patients were regularly followed up with assessment of thyroid function every 3 to 6 months
Phitayakorn, R., et al. (2009) [57]	260	70 (26.9)	48 (15)	217 (83.5)	12 (1-172)	NR	NR	Followed with annual serum TSH level
Piper, H. G., et al. (2005) [58]	99	12 (18.2)	46.5	46 (69.7)	Ж	TSH > 5.5 µlU/mL	٣	Variable. 70% of patients had an initial TSH drawn within the first 3 months, 12% within 4 to 6 months, 12% within 7 to 12 months, and 6% of patients did not have a TSH drawn within the first vear
Rathi A., S. D., Prasad B. (2017)	60	19 (31.7)	ЛЛ	56 (93.3)	Q	NR	2.58	TFT at 1 month, 3 months & 6 months
رحیا Said, M., et al. (2013) [60]	1240	417 (33.6)	51 (14)	1038 (83.7)	24	TSH > 4 µlU/mL	R	Median time to the first TSH blood test was 5 weeks
Salih, A. M. (2018) 611	166	1 (0.6)	42.68	139 (83.7)	24	NR	NR	NR
con Sancho, J. J., et al. (2012) [62]	47	14 (29.8)	41.36 (9.6)	46 (97.9)	55	NR	R	TSH and fT4 at 3, 6, and 12 months and vearly thereafter
Sarkis, L. M., et al. (2017) [63]	276	61 (22.1)	51.5 (15.8)	227 (82.3)	NR	TSH > 4.5 mIU/L	NR	TSH measured 6-8 weeks after surgery

Table 1 (continued)	(pa							
Article	Patient Number	Hypothyroid, No. (%)	Age, <i>years</i> , mean (SD)	Sex, female, No. (%)	Follow up duration <i>, months,</i> (range)	Definition of hypothyroidism	Interval to hypothyroidism from intervention, <i>months</i>	Thyroid function follow-up protocol
Seiberling, K. A., et al. (2007) [64]	58	14 (24.1)	46.5	44 (75.9)	24	TSH > 4 mIU/L	RN	At least one TSH within 6 weeks after surgerv
Sellami, M., et al. (2022) [65]	214	66 (30.8)	44 (14)	197 (92.1)	NR	TSH > 5 mlU/L	NR	NR
Spanheimer, P. M., et al. (2011) [66]	71	24 (33.8)	50.1	NR	7.7	TSH > 4.2 mIU/L	NR	TFTs at 6 weeks
Stoll, S. J., et al. (2009) [9]	547	78 (14.3)	50	440 (80.4)	32 (12–54)	T5H > 4.82 mIU/L	Я	A TSH level was meas- ured in all patients approximately 6 to 8 weeks after surgery during routine follow- up
Su, S. Y., et al. (2009) [67]	294	32 (10.9)	NR	252 (85.7)	15 (3-150)	TSH > 4 mIU/L	8.2	NN
Tomoda, C., et al. (2011) [68]	233	57 (24.5)	51	193 (82.8)	43.2	TSH > 5.0 mIU/I and normal free T4 level lasting for more than 3 months	ЛК	T5H at least 4–6 weeks after surgery. Serum T5H levels were subsequently followed every 3–6 months for at least 3 years
Vaiman, M., et al. (2008) [69]	1051	294 (28)	л Я	R	(24-360)	TSH > 6.0 mIU/L that persisted for at least 8 weeks after surgery	R	R
Wadström, C., et al. (1999) [70]	229	48 (21)	47	204 (89.1)	168 (12-396)	NR	NR	ZR
Wilson, M., et al. (2020) [71]	100	47 (47)	50.5 (16.2)	74 (74)	16	л Л	ИК	T5H at 6 weeks, 6 months, 12 months, and then annually following thyroid lobectomy
Wormald, R., et al. (2008) [72]	82	15 (18.3)	53	71 (86.6)	28 (18-38)	TSH > 4.5 mlU/L	5.4 - clinical hypothyroid group 12 - subclinical hypothyroid group	T5H between 3 and 6 months and at 12 months post-opera- tively. Thereafter, all patients underwent thyroid function test- ing on an annual basis

Article Patient Number Hypothyroid, No. Age, years, mean Sex, female, No. Fo (%) (%) (%) (%) (%) (%) (%) (%) Yetkin, G., et al. 104 24 (23) 44.9 (11.9) 92 (88.5) 39 Zo10) (73] 301 (73) 44.9 (11.9) 92 (88.5) 39				
. 104 24 (23) 44.9 (11.9) 92 (88.5)	Sex, female, No. (%)	Follow up Definition of duration <i>, months</i> , hypothyroidism (range)	Interval to hypothyroidism from intervention, months	Thyroid function follow-up protocol
		37) TSH > 5 mIU/L	XX	TSH and free thyroxine levels were meas- ured in all patients at the end of the first postoperative month. If the free thyroxine and TSH concentra- tions were normal, tions were normal, tions were normal, tions were without thy- roxine treatment

I Thyroxine, T3 Triiodothyronine
74
fT3 free triiodothyronine
fT4 free thyroxine,
test,
TFT Thyroid function 1
H,
g hormone
oid stimulating
Thyra
TSH
NR Not reported,




Fig. 1 PRISMA diagram illustrating selection of studies

Post-operative course of hypothyroidism

The average time to hypothyroidism or thyroxine initiation was reported in 19 studies. These values ranged between 1.7-24 months (Table 1). Twelve studies found the average onset of hypothyroidism or thyroxine initiation to be 3-6 months post-operatively.

In these studies 34% (95% CI, 21-47%; P<0.001) of postoperatively hypothyroid patients recovered to euthyroid status (Fig. 9), displaying transient hypothyroidism. Four papers assessed the factors associated with transient hypothyroidism [6–8, 13] (Sup. Table 2). Three studies found patients with a lower pre-operative TSH had a higher likelihood of returning to euthyroidism [6–8]. A funnel plot assessing transient hypothyroidism qualitatively showed asymmetry which may indicate publication bias (Sup. Figure 21).

Discussion

The incidence of hypothyroidism following hemithyroidectomy was 29%, and the incidence of thyroxine supplementation alone 23%. The higher rate for hypothyroidism reflects that many studies did not initiate thyroxine for

Study or Subgroup Inci Abraham et al. (2022) Ahn et al. (2016) Akkari et al. (2014) Aklasieh et al. (2017) Alsaleh et al. (2021) Al-Shalhoub et al. (2017) Antunes et al. (2013) Attaallah et al. (2013) Attaallah et al. (2013) Balentine et al. (2013) Barar et al. (2011) Barczynski et al. (2010) Bauer et al. (2013) Baisa et al. (2013) Beisa et al. (2013) Beisa et al. (2013) Beisa et al. (2013) Beisa et al. (2013) Beisa et al. (2013) Beisa et al. (2012) Chen et al. (2012) Chen et al. (2019) Cheung et al. (2019) Chotigavanich (2016) Chu et al. (2012) Chone et al. (2011) Cho et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) De Carlucci et al. (2014) Ha et al. (2015) Johner et al. (2014) Ha et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kim SY et al. (2020) Kim SY et al. (2017) Lankarani et al. (2017) Lankarani et al. (2017) Lankarani et al. (2003) L	0.6 0.21 0.34 0.37 0.22 0.57 0.28 0.24 0.19 0.20 0.20 0.20 0.20 0.21 0.21 0.21 0.21	0.037 0.021 0.11 0.077 0.055 0.046 0.026 0.121 0.043 0.05 0.019 0.037 0.028 0.037 0.028 0.034 0.023 0.067 0.033 0.036 0.037 0.075 0.044 0.022 0.044 0.022 0.044 0.022 0.037	$\begin{array}{c} 1.6\% \\ 1.6\% \\ 1.2\% \\ 1.4\% \\ 1.5\% \\ 1.5\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.$	IV, Random, 95% Cl 0.37 [0.30, 0.44] 0.60 [0.56, 0.64] 0.21 [-0.01, 0.43] 0.34 [0.19, 0.49] 0.45 [0.34, 0.56] 0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48] 0.16 [0.06, 0.26]	IV, Random, 95% CI
Ahn et al. (2016) Akkari et al. (2014) Alsaleh et al. (2021) Al-Shalhoub et al. (2017) Antunes et al. (2013) Attaallah et al. (2013) Balentine et al. (2013) Barar et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2021) Chen et al. (2022) Chen et al. (2022) Chen et al. (2021) Cho et al. (2019) Choug et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2012) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2018) Dou et al. (2019) Tho et al. (2019) Chotigavanich (2016) Chu et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2018) Dou et al. (2019) Ito et al. (2017) Kim CJ et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Kee et al. (2020) Lee et al. (2015)	0.6 0.21 0.34 0.37 0.22 0.57 0.28 0.24 0.19 0.20 0.20 0.20 0.20 0.21 0.21 0.21 0.21	0.021 0.11 0.077 0.055 0.046 0.026 0.121 0.043 0.057 0.019 0.037 0.028 0.034 0.033 0.067 0.033 0.036 0.037 0.044 0.022 0.044 0.022 0.037 0.036 0.036 0.032	$\begin{array}{c} 1.6\% \\ 1.2\% \\ 1.4\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.5\% \end{array}$	0.60 [0.56, 0.64] 0.21 [-0.01, 0.43] 0.34 [0.19, 0.49] 0.45 [0.34, 0.56] 0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.20 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Akkari et al. (2014) Alsaleh et al. (2021) Al-Shalhoub et al. (2017) Antunes et al. (2013) Battaallah et al. (2013) Baran et al. (2013) Barar et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2021) Choe et al. (2019) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Cho et al. (2012) Cho et al. (2012) Chot et al. (2013) Buehler et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kim SY et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.21 0.34 0.45 0.37 0.22 0.57 0.28 0.24 0.29 0.26 0.13 0.22 0.21 0.21 0.21 0.23 0.21 0.24 0.23 0.21 0.23 0.21	0.11 0.077 0.055 0.046 0.121 0.043 0.012 0.037 0.028 0.037 0.033 0.067 0.033 0.067 0.033 0.036 0.037 0.044 0.022 0.044 0.022 0.044 0.022 0.037	$\begin{array}{c} 1.2\% \\ 1.4\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.5\% \end{array}$	0.21 [-0.01, 0.43] 0.34 [0.19, 0.49] 0.45 [0.34, 0.56] 0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Alsaleh et al. (2021) Al-Shalhoub et al. (2017) Antunes et al. (2013) Attaallah et al. (2015) Balentine et al. (2013) Baran et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Cho et al. (2012) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2014) Ha et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.34 0.45 0.37 0.22 0.57 0.28 0.24 0.19 0.28 0.22 0.21 0.22 0.21 0.23 0.27 0.14 0.36 0.41 0.36 0.5 0.37 0.21	0.055 0.046 0.026 0.121 0.043 0.05 0.019 0.037 0.028 0.033 0.036 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.044 0.022 0.037 0.035 0.042 0.037	$\begin{array}{c} 1.4\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.1\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \end{array}$	0.34 [0.19, 0.49] 0.45 [0.34, 0.56] 0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.16, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Al-Shalhoub et al. (2017) Antunes et al. (2013) Attaallah et al. (2015) Balentine et al. (2013) Baran et al. (2021) Barzzynski et al. (2010) Bauer et al. (2013) Beisa et al. (2013) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2022) Chen et al. (2019) Choig et al. (2019) Chotigawanich (2021) Cho et al. (2011) Cho et al. (2012) Chot get al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2019) Ito et al. (2015) Isoner et al. (2014) Ha et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kim SY et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.45 0.37 0.22 0.57 0.28 0.24 0.19 0.22 0.24 0.29 0.26 0.13 0.22 0.21 0.21 0.21 0.21 0.36 0.41 0.5 0.37 0.21	0.055 0.046 0.026 0.121 0.043 0.05 0.019 0.037 0.028 0.033 0.036 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.044 0.022 0.037 0.035 0.042 0.037	$\begin{array}{c} 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \end{array}$	0.45 [0.34, 0.56] 0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Antunes et al. (2013) Attaallah et al. (2013) Balentine et al. (2013) Baran et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2013) Beisa et al. (2011) Beisa et al. (2021) Cao et al. (2022) Chen et al. (2022) Chen et al. (2019) Choung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2012) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) De tal. (2013) Ergul et al. (2014) Ha et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kim SY et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.37 0.22 0.57 0.28 0.24 0.19 0.22 0.46 0.22 0.26 0.23 0.21 0.21 0.21 0.36 0.41 0.36 0.41 0.5 0.5 0.37 0.21	0.046 0.026 0.121 0.043 0.055 0.019 0.037 0.028 0.023 0.067 0.033 0.036 0.037 0.075 0.044 0.022 0.044 0.022 0.044 0.022 0.037 0.035 0.038 0.038 0.039	$1.5\% \\ 1.6\% \\ 1.1\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ $	0.37 [0.28, 0.46] 0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Attaallah et al. (2015) Balentine et al. (2013) Baran et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2013) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2022) Chen et al. (2019) Choug et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2012) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) Dou et al. (2014) Ha et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Koh et al. (2020) Koh et al. (2020) Koh et al. (2017) Lankarani et al. (2008) Lee et al. (2015)	0.22 0.57 0.28 0.24 0.19 0.18 0.22 0.46 0.29 0.26 0.13 0.21 0.21 0.21 0.21 0.36 0.41 0.36 0.41 0.5 0.5 0.37 0.21	0.026 0.121 0.043 0.05 0.019 0.037 0.028 0.034 0.033 0.036 0.033 0.036 0.044 0.022 0.044 0.022 0.044 0.022 0.037 0.036 0.032 0.038 0.039	$1.6\% \\ 1.1\% \\ 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ $	0.22 [0.17, 0.27] 0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Balentine et al. (2013) Baran et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2029) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Cho et al. (2012) Chot gavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) Do tarluci et al. (2008) Dou et al. (2017) Isto et al. (2011) Kim CJ et al. (2017) Kinstensen et al. (2018) Kristensen et al. (2008) Lang et al. (2017) Lankarani et al. (2008) Lee et al. (2015)	0.57 0.28 0.24 0.19 0.18 0.22 0.46 0.29 0.26 0.13 0.21 0.21 0.21 0.23 0.27 0.14 0.36 0.41 0.36 0.5 0.5 0.5	0.121 0.043 0.05 0.019 0.037 0.028 0.034 0.067 0.033 0.036 0.037 0.075 0.044 0.022 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$1.1\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.5\% \\ $	0.57 [0.33, 0.81] 0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Baran et al. (2021) Barczynski et al. (2010) Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2029) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Cho et al. (2011) Cho et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) De Carlucci et al. (2008) Dou et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Kifstensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2020)	0.28 0.24 0.19 0.18 0.29 0.26 0.13 0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.36 0.41 0.5 0.37 0.21	0.043 0.05 0.019 0.028 0.034 0.023 0.067 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$\begin{array}{c} 1.5\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \end{array}$	0.28 [0.20, 0.36] 0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2011) Beisa et al. (2021) Cao et al. (2022) Chen et al. (2022) Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Chong et al. (2012) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) Dou et al. (2014) Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Lee et al. (2015)	0.19 0.18 0.22 0.46 0.29 0.26 0.13 0.2 0.21 0.21 0.23 0.27 0.14 0.36 0.41 0.36 0.5 0.37 0.21	0.019 0.037 0.028 0.034 0.033 0.036 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$\begin{array}{c} 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \end{array}$	0.24 [0.14, 0.34] 0.19 [0.15, 0.23] 0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Bauer et al. (2013) Beisa et al. (2011) Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) Do u et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.19 0.18 0.22 0.46 0.29 0.26 0.13 0.2 0.21 0.21 0.23 0.27 0.14 0.36 0.41 0.36 0.5 0.37 0.21	0.037 0.028 0.034 0.023 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$\begin{array}{c} 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \end{array}$	0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Beisa et al. (2015) Buehler et al. (2021) Cao et al. (2022) Chen et al. (2019) Chig and al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) Ergul et al. (2014) Ha et al. (2015) Johner et al. (2020) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2017) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.18 0.22 0.46 0.29 0.26 0.13 0.21 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.037 0.028 0.034 0.023 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$1.6\% \\ 1.6\% \\ 1.6\% \\ 1.4\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ $	0.18 [0.11, 0.25] 0.22 [0.17, 0.27] 0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Buehler et al. (2021) Cao et al. (2022) Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2011) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2012) De Carlucci et al. (2008) Chou et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2020) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.46 0.29 0.26 0.13 0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.034 0.023 0.067 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.6% 1.6% 1.6% 1.6% 1.4% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.5%	0.46 [0.39, 0.53] 0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Cao et al. (2022) Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2015) Iohner et al. (2020) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.29 0.26 0.13 0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.023 0.067 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.4% 1.6% 1.6% 1.4% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.5%	0.29 [0.24, 0.34] 0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Chen et al. (2019) Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Choot et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2020) Kim SY et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.26 0.13 0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.067 0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$1.4\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.4\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ $	0.26 [0.13, 0.39] 0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Cheung et al. (1986) Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Let et al. (2020) Ken et al. (2017) Chantani et al. (2008) Let et al. (2015)	0.13 0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.033 0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	$1.6\% \\ 1.6\% \\ 1.6\% \\ 1.4\% \\ 1.6\% \\ 1.5\% \\ 1.6\% \\ 1.6\% \\ 1.6\% \\ 1.5\% \\ $	0.13 [0.07, 0.19] 0.20 [0.13, 0.27] 0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Chidambaranathan (2021) Cho et al. (2011) Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.2 0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.036 0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.6% 1.4% 1.6% 1.6% 1.6% 1.6% 1.6% 1.5%	$\begin{array}{c} 0.20 \; [0.13, \; 0.27] \\ 0.21 \; [0.14, \; 0.28] \\ 0.21 \; [0.06, \; 0.36] \\ 0.23 \; [0.15, \; 0.31] \\ 0.27 \; [0.18, \; 0.36] \\ 0.14 \; [0.10, \; 0.18] \\ 0.36 \; [0.29, \; 0.43] \\ 0.41 \; [0.34, \; 0.48] \end{array}$	
Cho et al. (2011) Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2020) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.037 0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.4% 1.6% 1.6% 1.6% 1.6% 1.6% 1.5%	0.21 [0.14, 0.28] 0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Cho et al. (2021) Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.21 0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.075 0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.4% 1.6% 1.5% 1.6% 1.6% 1.6% 1.5%	0.21 [0.06, 0.36] 0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Chong et al. (2019) Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.23 0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.042 0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.5% 1.6% 1.6% 1.6% 1.5%	0.23 [0.15, 0.31] 0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Chotigavanich (2016) Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.27 0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.044 0.022 0.037 0.036 0.052 0.038 0.039	1.5% 1.6% 1.6% 1.6% 1.5%	0.27 [0.18, 0.36] 0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Chu et al. (2012) De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Iohner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.14 0.36 0.41 0.16 0.5 0.37 0.21	0.022 0.037 0.036 0.052 0.038 0.039	1.6% 1.6% 1.6% 1.5%	0.14 [0.10, 0.18] 0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
De Carlucci et al. (2008) Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.36 0.41 0.16 0.5 0.37 0.21	0.037 0.036 0.052 0.038 0.039	1.6% 1.6% 1.5%	0.36 [0.29, 0.43] 0.41 [0.34, 0.48]	
Dou et al. (2020) Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.41 0.16 0.5 0.37 0.21	0.036 0.052 0.038 0.039	1.6% 1.5%	0.41 [0.34, 0.48]	
Ergul et al. (2014) Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.16 0.5 0.37 0.21	0.052 0.038 0.039	1.5%		· · · · ·
Ha et al. (2019) Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.5 0.37 0.21	0.038 0.039		0.16 [0.06, 0.26]	
Ito et al. (2015) Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.37 0.21	0.039			
Johner et al. (2011) Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.21		1.6%	0.50 [0.43, 0.57]	
Kim CJ et al. (2020) Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)		0 0 2 0	1.6%	0.37 [0.29, 0.45]	
Kim SY et al. (2020) Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.39	0.038	1.6%	0.21 [0.14, 0.28]	
Koh et al. (2008) Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)		0.031	1.6%	0.39 [0.33, 0.45]	-
Kristensen et al. (2014) Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.66	0.031	1.6%	0.66 [0.60, 0.72]	
Lang et al. (2017) Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.43	0.042	1.6%	0.43 [0.35, 0.51]	
Lankarani et al. (2008) Latoo et al. (2020) Lee et al. (2015)	0.29	0.085	1.3%	0.29 [0.12, 0.46]	
Latoo et al. (2020) Lee et al. (2015)	0.29	0.037	1.6%	0.29 [0.22, 0.36]	
Lee et al. (2015)	0.18	0.057	1.5%	0.18 [0.07, 0.29]	
	0.36	0.068	1.4%	0.36 [0.23, 0.49]	
Lee et al. (2021)		0.026	1.6%	0.24 [0.19, 0.29]	
		0.026	1.6%	0.55 [0.50, 0.60]	
Lindblom et al. (2001)		0.057	1.5%	0.18 [0.07, 0.29]	
McHenry et al. (2000)		0.057	1.5%	0.35 [0.24, 0.46]	
Meyer et al. (2020)		0.024	1.6%	0.30 [0.25, 0.35]	-
Miller et al. (2006)		0.047	1.5%	0.27 [0.18, 0.36]	
Moon et al. (2008)		0.048	1.5%	0.37 [0.28, 0.46]	
Morris et al. (2013)	0.46	0.05	1.5%	0.46 [0.36, 0.56]	
Ng et al. (2019)		0.011	1.6%	0.14 [0.12, 0.16]	-
Noureldine et al. (2013)		0.029	1.6%	0.10 [0.04, 0.16]	
Park et al. (2017)		0.026	1.6%	0.64 [0.59, 0.69]	
Phitayakorn et al. (2009)		0.028	1.6%	0.27 [0.22, 0.32]	
Piper et al. (2005)		0.047	1.5%	0.18 [0.09, 0.27]	
Rathi et al. (2017)	0.32	0.06	1.5%	0.32 [0.20, 0.44]	
Said et al. (2013)		0.013	1.6%	0.34 [0.31, 0.37]	
Salih et al. (2018)		0.006	1.6%	0.01 [-0.00, 0.02]	
Sancho et al. (2012)		0.067	1.4%	0.30 [0.17, 0.43]	
Sarkis et al. (2017)		0.025	1.6%	0.22 [0.17, 0.27]	-
Seiberling et al. (2007)		0.056	1.5%	0.24 [0.13, 0.35]	
Sellami et al. (2022)		0.032	1.6%	0.31 [0.25, 0.37]	
Spanheimer et al. (2011)		0.056	1.5%	0.34 [0.23, 0.45]	
Stoll et al. (2009)		0.015	1.6%	0.14 [0.11, 0.17]	
Su et al. (2009) Tamada at al. (2011)		0.018	1.6%	0.11 [0.07, 0.15]	* _
Tomoda et al. (2011)		0.028	1.6%	0.24 [0.19, 0.29]	_
Vaiman et al. (2008)		0.014	1.6%	0.28 [0.25, 0.31]	
Wadström et al. (1999)		0.027	1.6%	0.21 [0.16, 0.26]	-
Wilson et al. (2020)	0.47	0.05	1.5%	0.47 [0.37, 0.57]	
Wormald et al. (2008)		0.043	1.5%	0.18 [0.10, 0.26]	
Yetkin et al. (2010)	0.23	0.041	1.6%	0.23 [0.15, 0.31]	
Total (95% CI)			100.0%	0.29 [0.25, 0.34]	
Heterogeneity: Tau ² = 0.03; Chi ²	2705				

Fig. 2 Individual and pooled incidence of hypothyroidism following hemithyroidectomy

				Incidence	Incidence
Study or Subgroup	Incidence	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ahn et al. (2016)	0.143	0.017	2.5%	0.14 [0.11, 0.18]	-
Alsaleh et al. (2021)	0.342	0.077	1.9%	0.34 [0.19, 0.49]	
Attaallah et al. (2015)	0.216	0.026	2.5%	0.22 [0.17, 0.27]	-
Balentine et al. (2013)	0.471	0.121	1.4%	0.47 [0.23, 0.71]	
Baran et al. (2021)	0.127	0.032	2.4%	0.13 [0.06, 0.19]	
Bauer et al. (2013)	0.188	0.019	2.5%	0.19 [0.15, 0.23]	-
Cao et al. (2022)	0.148	0.018	2.5%	0.15 [0.11, 0.18]	-
Chen et al. (2019)	0.163	0.056	2.2%	0.16 [0.05, 0.27]	
Chidambaranathan (2021)	0.117	0.028	2.5%	0.12 [0.06, 0.17]	-
Chu et al. (2012)	0.076	0.016	2.5%	0.08 [0.04, 0.11]	-
Dou et al. (2020)	0.258	0.032	2.4%	0.26 [0.20, 0.32]	-
Ergul et al. (2014)	0.08	0.038	2.4%	0.08 [0.01, 0.15]	
Ha et al. (2019)	0.497	0.038	2.4%	0.50 [0.42, 0.57]	
lto et al. (2015)	0.373	0.039	2.4%	0.37 [0.30, 0.45]	
Johner et al. (2011)	0.103	0.028	2.5%	0.10 [0.05, 0.16]	-
Kim CJ et al. (2020)	0.389	0.031	2.4%	0.39 [0.33, 0.45]	
Kim SY et al. (2020)	0.66	0.03	2.5%	0.66 [0.60, 0.72]	
Koh et al. (2008)	0.088	0.024	2.5%	0.09 [0.04, 0.14]	-
Kristensen et al. (2014)	0.286	0.085	1.8%	0.29 [0.12, 0.45]	
Lang et al. (2017)	0.067	0.02	2.5%	0.07 [0.03, 0.11]	-
Lee et al. (2015)	0.236	0.026	2.5%	0.24 [0.19, 0.29]	-
Lee et al. (2021)	0.431	0.026	2.5%	0.43 [0.38, 0.48]	
Meyer et al. (2020)	0.301	0.024	2.5%	0.30 [0.25, 0.35]	-
Morris et al. (2013)	0.459	0.05	2.2%	0.46 [0.36, 0.56]	
Ng et al. (2019)	0.102	0.01	2.6%	0.10 [0.08, 0.12]	-
Noureldine et al. (2013)	0.095	0.029	2.5%	0.10 [0.04, 0.15]	
Park et al. (2017)	0.119	0.018	2.5%	0.12 [0.08, 0.15]	-
Phitayakorn et al. (2009)	0.269	0.028	2.5%	0.27 [0.21, 0.32]	
Piper et al. (2005)	0.091	0.035	2.4%	0.09 [0.02, 0.16]	
Rathi et al. (2017)	0.317	0.06	2.1%	0.32 [0.20, 0.43]	
Said et al. (2013)	0.253	0.012	2.6%	0.25 [0.23, 0.28]	-
Salih et al. (2018)	0.006	0.006	2.6%	0.01 [-0.01, 0.02]	+
Sancho et al. (2012)	0.298	0.067	2.0%	0.30 [0.17, 0.43]	
Sarkis et al. (2017)	0.138	0.021	2.5%	0.14 [0.10, 0.18]	-
Spanheimer et al. (2011)	0.338	0.056	2.2%	0.34 [0.23, 0.45]	
Stoll et al. (2009)	0.143	0.015	2.5%	0.14 [0.11, 0.17]	-
Su et al. (2009)		0.015	2.5%	0.07 [0.05, 0.10]	-
Tomoda et al. (2011)	0.245	0.028	2.5%	0.24 [0.19, 0.30]	
Vaiman et al. (2008)	0.28	0.014	2.6%	0.28 [0.25, 0.31]	-
Wadström et al. (1999)	0.236	0.028	2.5%	0.24 [0.18, 0.29]	-
Wilson et al. (2020)	0.47	0.05	2.2%	0.47 [0.37, 0.57]	
Wormald et al. (2008)	0.183	0.043	2.3%	0.18 [0.10, 0.27]	
Total (95% CI)			100.0%	0.23 [0.19, 0.27]	•
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 1642$	2.95, df	= 41 (P <	< 0.00001); I ² = 98%	
Test for overall effect: $Z = 1$					-1 -0.5 0 0.5 1

Fig. 3 Individual and pooled incidence of thyroxine supplementation following hemithyroidectomy

biochemical hypothyroidism alone but typically for clinical or overt hypothyroidism or TSH significantly above the upper limit of normal. The incidence of overt hypothyroidism was 4% which may be of significance for the clinician and patient due to its health effects.

A high degree of heterogeneity was recorded in the pooled incidence of hypothyroidism, thyroxine supplementation, and overt or clinical hypothyroidism. This may be explained by the differences in study follow up protocol, definitions for hypothyroidism, or indications for thyroxine supplementation. The first thyroid function (TF) measurements occurred at varying times, ranging from 1 week to 3-6 months post-surgery. Further, follow up protocol varied by duration of follow up, as well as frequency of thyroid function measurements; the follow up duration ranged from 6 to 168 months, and thyroid function measurements ranged from occurring only once, to several times at regular intervals. Studies typically defined hypothyroidism as an increase in TSH above the upper limit of normal, however the accepted upper limit of normal at each institution ranged from 3.74 to 6 μ IU/mL⁵. Greater frequency of TF measurements,

				Incidence	Incidence
Study or Subgroup	Incidence	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ahn et al. (2016)	0.027	0.008	16.4%	0.03 [0.01, 0.04]	
Cao et al. (2022)	0.016	0.006	17.2%	0.02 [0.00, 0.03]	-
Chong et al. (2019)	0.04	0.019	10.8%	0.04 [0.00, 0.08]	
Ergul et al. (2014)	0.08	0.038	4.8%	0.08 [0.01, 0.15]	
Koh et al. (2008)	0.081	0.023	9.0%	0.08 [0.04, 0.13]	
Lang et al. (2017)	0.033	0.015	12.8%	0.03 [0.00, 0.06]	
Lee et al. (2021)	0.102	0.016	12.2%	0.10 [0.07, 0.13]	_
Park et al. (2017)	0.015	0.007	16.8%	0.01 [0.00, 0.03]	-
Total (95% CI)			100.0%	0.04 [0.02, 0.06]	•
Heterogeneity: Tau ² =	= 0.00; Chi ² =	= 36.32			
Test for overall effect:					-0.2 -0.1 0 0.1 0.2

Fig. 4 Individual and pooled incidence of overt hypothyroidism following hemithyroidectomy

	TSH	≥2	TSH ·	<2		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Abraham et al. (2022)	27	36	36	134	15.9%	2.79 [1.99, 3.91]	
Ahn et al. (2016)	162	214	64	191	25.9%	2.26 [1.82, 2.80]	-
Cho et al. (2011)	16	35	7	64	4.1%	4.18 [1.90, 9.18]	
Chong et al. (2019)	16	28	7	73	4.2%	5.96 [2.75, 12.92]	
Chotigavanich (2016)	14	24	13	76	6.6%	3.41 [1.87, 6.21]	
De Carlucci et al. (2008)	48	95	13	91	7.9%	3.54 [2.06, 6.08]	
Said et al. (2013)	124	162	293	1078	35.4%	2.82 [2.47, 3.21]	-
Total (95% CI)		594		1707	100.0%	2.87 [2.43, 3.40]	•
Total events Heterogeneity: Tau ² = 0.0	407 2: Chi ² =	9.63.	433 df = 6 (P	%			
Test for overall effect: Z =				0.05 0.2 1 5 20			

Fig. 5 Individual and pooled RR for TSH >2 between hypothyroid and euthyroid groups following hemithyroidectomy

	Нур	othyroi	d	Eu	thyroid			Mean Difference	Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Ran	dom, 95% Cl
Ahn et al. (2016)	47.5	14.25	226	47.2	17	179	4.3%	0.30 [-2.81, 3.41]	-	
Baran et al. (2021)	15.5	2.15	31	15.8	2.22	79	6.2%	-0.30 [-1.20, 0.60]		-
Beisa et al. (2011)	52.9	13.9	48	41.6	14.1	168	3.1%	11.30 [6.83, 15.77]		
Beisa et al. (2015)	44.2	17.8	20	42.3	11.8	89	1.4%	1.90 [-6.28, 10.08]		
Buehler et al. (2021)	52.2	16.7	96	48.7	14.6	114	3.2%	3.50 [-0.78, 7.78]		+
Cao et al. (2022)	48.61	10.91	110	48.68	12.25	268	4.8%	-0.07 [-2.58, 2.44]	-	-+
Chen et al. (2019)	13.5	3.72	11	13.7	2.84	32	4.9%	-0.20 [-2.61, 2.21]	-	
Cho et al. (2011)	40.1	12.5	26	40.2	13.25	97	2.5%	-0.10 [-5.58, 5.38]		
Chotigavanich (2016)	44.2	11.7	27	43.3	12.4	73	2.6%	0.90 [-4.35, 6.15]		_ <u>+</u>
Chu et al. (2012)	53.5	15.53	38	47	16.3	225	2.5%	6.50 [1.12, 11.88]		
Dou et al. (2020)	40.9	11.2	77	40.2	9.9	113	4.3%	0.70 [-2.40, 3.80]		
Ha et al. (2019)	45.3	11.6	87	45.2	12.8	88	3.8%	0.10 [-3.52, 3.72]	-	
Kim CJ et al. (2020)	51.1	11.8	98	45.5	13.7	154	4.2%	5.60 [2.42, 8.78]		
Kim SY et al. (2020)	44.04	11.28	169	43.31	10.21	87	4.6%	0.73 [-2.01, 3.47]		_
Koh et al. (2008)	42.3	12.3	58	42.88	11.4	78	3.4%	-0.58 [-4.63, 3.47]		
Lang et al. (2017)	54.86	16.12	44	50.95	12.98	106	2.5%	3.91 [-1.46, 9.28]		+
Lee et al. (2021)	45.5	12.3	193	46.3	12.4	160	4.8%	-0.80 [-3.39, 1.79]	-	
McHenry et al. (2000)	47	16	25	44	16	46	1.5%	3.00 [-4.79, 10.79]		
Meyer et al. (2020)	46.6	12.4	111	42.6	12.3	258	4.6%	4.00 [1.25, 6.75]		
Moon et al. (2008)	47.35	15.2	37	47.7	11.1	64	2.4%	-0.35 [-5.95, 5.25]		
Ng et al. (2019)	49.7	18.25	123	45.5	17	778	3.9%	4.20 [0.76, 7.64]		
Noureldine et al. (2013)	58.1	9.1	10	47.8	11.8	95	2.1%	10.30 [4.18, 16.42]		
Park et al. (2017)	48.5	10.8	215	46.8	10.1	120	5.0%	1.70 [-0.61, 4.01]		+
Rathi et al. (2017)	39.42	9.5	19	36.36	8	41	2.8%	3.06 [-1.86, 7.98]		+
Sellami et al. (2022)	44	16	66	44	13	148	3.2%	0.00 [-4.39, 4.39]		_ _
Stoll et al. (2009)	52	17.66	78	49	21.65	469	3.2%	3.00 [-1.38, 7.38]		+
Su et al. (2009)	54.5	13	32	49.5	15.75	262	2.8%	5.00 [0.11, 9.89]		
Tomoda et al. (2011)	56.2	13	57	48.97	15	176	3.4%	7.23 [3.19, 11.27]		
Wilson et al. (2020)	51.4	17	47	49.7	15.5	53	2.0%	1.70 [-4.71, 8.11]		
Total (95% CI)			2179			4620	100.0%	2.29 [1.20, 3.38]		•
Heterogeneity: Tau ² = 4. ⁻ Test for overall effect: Z =				28 (P <	0.0000	1); $I^2 =$	64%		-20 -10	0 10

Fig. 6 Individual and pooled WMD for age between hypothyroid and euthyroid groups following hemithyroidectomy

	Fema	le	Male	2		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Abraham et al. (2022)	55	140	8	30	2.2%	1.47 [0.79, 2.76]	
Ahn et al. (2016)	202	345	24	60	6.0%	1.46 [1.06, 2.02]	
Al-Shalhoub et al. (2017)	33	67	4	16	1.2%	1.97 [0.81, 4.76]	
Baran et al. (2021)	27	87	4	15	1.2%	1.16 [0.48, 2.85]	
Beisa et al. (2011)	41	194	7	22	2.0%	0.66 [0.34, 1.30]	
Beisa et al. (2015)	17	91	3	18	0.8%	1.12 [0.37, 3.43]	
Buehler et al. (2021)	51	135	17	47	4.0%	1.04 [0.67, 1.62]	
Cao et al. (2022)	88	280	22	98	4.4%	1.40 [0.93, 2.10]	— —
Chen et al. (2019)	8	34	3	9	0.8%	0.71 [0.23, 2.13]	
Cho et al. (2011)	20	87	6	36	1.4%	1.38 [0.60, 3.15]	
Chotigavanich (2016)	23	93	4	7	1.7%	0.43 [0.21, 0.90]	
Chu et al. (2012)	30	204	8	59	1.7%	1.08 [0.53, 2.24]	
De Carlucci et al. (2008)	56	163	5	23	1.4%	1.58 [0.71, 3.53]	
Dou et al. (2020)	62	140	15	50	3.6%	1.48 [0.93, 2.34]	—
Ha et al. (2019)	81	148	6	27	1.7%	2.46 [1.20, 5.06]	
Kim CJ et al. (2020)	18	47	80	205	4.5%	0.98 [0.66, 1.47]	_ _
Kim SY et al. (2020)	134	204	35	52	9.0%	0.98 [0.79, 1.21]	-4-
Koh et al. (2008)	54	115	4	21	1.2%	2.47 [1.00, 6.08]	
Lang et al. (2017)	39	125	5	25	1.4%	1.56 [0.68, 3.56]	
Lee et al. (2021)	152	256	41	97	7.8%	1.40 [1.09, 1.81]	
McHenry et al. (2000)	20	59	5	12	1.6%	0.81 [0.38, 1.74]	
Meyer et al. (2020)	87	278	24	91	4.8%	1.19 [0.81, 1.74]	- -
Miller et al. (2006)	22	73	2	17	0.5%	2.56 [0.67, 9.86]	
Moon et al. (2008)	31	76	6	25	1.6%	1.70 [0.80, 3.59]	
Ng et al. (2019)	95	682	28	219	4.6%	1.09 [0.74, 1.61]	
Noureldine et al. (2013)	9	88	1	17	0.3%	1.74 [0.24, 12.84]	
Park et al. (2017)	178	263	37	72	8.2%	1.32 [1.04, 1.67]	_ _ _
Rathi et al. (2017)	18	56	1	4	0.3%	1.29 [0.23, 7.32]	
Said et al. (2013)	344	1038	73	202	9.4%	0.92 [0.75, 1.12]	
Seiberling et al. (2007)	11	44	3	14	0.8%	1.17 [0.38, 3.60]	
Sellami et al. (2022)	62	197	4	17	1.2%	1.34 [0.55, 3.23]	
Stoll et al. (2009)	69	440	9	107	2.0%	1.86 [0.96, 3.61]	
Su et al. (2009)	28	252	4	42	1.0%	1.17 [0.43, 3.16]	<u> </u>
Tomoda et al. (2011)	50	193	8	40	2.0%	1.30 [0.67, 2.52]	
Wilson et al. (2020)	34	74	13	26	3.7%	0.92 [0.58, 1.45]	— <u> </u>
Total (95% CI)		6768		1822	100.0%	1.19 [1.08, 1.32]	◆
Total events	2249		519				
Heterogeneity: Tau ² = 0.02 Test for overall effect: Z =	,	,		P = 0.1	.2); I ² = 2	3%	0.1 0.2 0.5 1 2 5 10

Fig. 7 Individual and pooled RR for female sex between hypothyroid and euthyroid groups following hemithyroidectomy

Study or Subgroup	log[Risk Ratio]	SE	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
Ahn et al. (2016)	0.3462	0.0852	17.0%	1.41 [1.20, 1.67]	
Cao et al. (2022)	0.49	0.2161	12.5%	1.63 [1.07, 2.49]	
Dou et al. (2020)	0.7948	0.1612	14.5%	2.21 [1.61, 3.04]	_
Ha et al. (2019)	0.2151	0.2005	13.0%	1.24 [0.84, 1.84]	- +
Miller et al. (2006)	1.1208	0.3145	9.2%	3.07 [1.66, 5.68]	
Ng et al. (2019)	1.0008	0.1655	14.3%	2.72 [1.97, 3.76]	
Stoll et al. (2009)	1.0575	0.2092	12.7%	2.88 [1.91, 4.34]	
Su et al. (2009)	1.1044	0.4179	6.7%	3.02 [1.33, 6.84]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)			100.0%	2.05 [1.57, 2.68]	•
Heterogeneity: Tau ² :	= 0.10; Chi ² = 29.				
Test for overall effect		0.2 0.5 1 2 5			

Fig. 8 Individual and pooled RR for Hashimoto's thyroiditis between hypothyroid and euthyroid groups following hemithyroidectomy

and greater duration of follow up, as well as a more liberal definition of hypothyroidism will likely increase the detection of hypothyroidism. Further, the surgical definition of hemithyroidectomy varied, with some studies characterising the procedure by lobectomy plus isthmusectomy, and others by lobectomy alone [13]. Resection of the isthmus may reduce the total thyroid volume and reduce the post-operative thyroid function, further




Fig. 9 Individual and pooled incidence of transient hypothyroidism following hemithyroidectomy

adding to the variation. Finally, some studies administered thyroxine for any elevation of TSH above the normal range while others only for clinically symptomatic or overtly hypothyroid patients, which may contribute to the high degree of heterogeneity.

The risk factors identified for the development of hypothyroidism included higher pre-operative TSH, older age, female sex, Hashimoto's thyroiditis, thyroid autoantibodies, and right sided hemithyroidectomy.

Higher pre-operative TSH levels are regularly cited as a risk factor for hypothyroidism. A higher TSH level indicates that the thyroid may already be dysfunctional prior to surgery, and more vulnerable to hypothyroidism. Older age was also found to be significantly associated. Age has been observed to be associated with thyroid decline and elevated TSH levels [76–78], with studies showing a TSH increase of 0.08 mU/L per decade of age [79] which may explain the preponderance of older patients in the hypothyroid group. Females were at increased risk of hypothyroidism which may be due to a higher rate of concomitant thyroid disorders amongst women [11], such as Hashimoto's which has been reported amongst women at a rate five times men [78].

Auto-antibodies are associated with thyroiditis and play a role in the auto-immune mediated dysfunction of the thyroid gland [80], likely explaining the association of auto-autoantibodies with hypothyroidism. The side of hemithyroidectomy may also significantly increase the risk of hypothyroidism. Hashimoto's thyroiditis is the most common subset of thyroiditis and is characterised by auto-immune destruction and progressive fibrosis of the thyroid gland [79], leading to thyroid dysfunction. Some studies have shown thyroid lobe asymmetry with the right lobe larger than the left [81, 82], possibly explaining the higher incidence of hypothyroidism in right sided hemithyroidectomy.

This study was novel in its analysis of post-operative thyroid function course, with the majority of studies finding the average onset of hypothyroidism or thyroxine initiation to be 3-6 months post-operatively. In a practical sense this can raise the awareness of early postoperative hypothyroidism and guide patient follow up. The pooled incidence of transient hypothyroidism representing spontaneous recovery of thyroid function without thyroxine supplementation was 34%. This may reflect gradual thyroid compensation. Seven studies reported average post-operative TSH levels at multiple time points post-operatively [8, 12, 25, 27, 45, 60, 68]. In six studies, the post-operative TSH peaked within 6 months, before declining over the subsequent months, in one study returning from a mean of 4.21 to 2.85 μ IU/ mL between 3 and 12 months postoperatively [12]. This natural recovery of thyroid function and decline in TSH level may explain the incidence of transient hypothyroidism. This indicates the need for regular follow up and monitoring of thyroid function. Transient hypothyroidism may also affect the interpretation of hypothyroid risk, with the incidence potentially higher than the prevalence.

This study is limited in a couple of respects. Firstly, studies reported hypothyroidism or initiated thyroxine supplementation according to a wide range of definitions or indications. Second studies followed institution dependant follow up protocols which varied significantly by their duration and the frequency of measurement. This lack of consistency across studies will reduce the applicability of our findings. Finally, the administration of levothyroxine in hypothyroid patients may mask a recovery in thyroid function, which may affect the observed rate of transient hypothyroidism.

This systematic review and meta-analysis is useful for clinicians in advising patients on post-operative risks and choosing the most suitable intervention for the patient. Those at high risk for hypothyroidism may elect to defer surgery if this is open to them or choose to undergo a total thyroidectomy to limit recurrence of the pathology being treated. Further, awareness of the post-surgical hypothyroid time course will inform follow up regimens and improve awareness of transient hypothyroidism which may reduce unnecessary treatment of biochemical hypothyroidism.

Conclusion

This systematic review and meta-analysis found the incidence of hypothyroidism post-hemithyroidectomy to be high suggesting the needs for better treatment strategy including more careful surgical approach by the surgeon to reduce this associated complication of hemithyroidectomy among the patients at risk. Higher pre-operative TSH, older age, female sex, Hashimoto's thyroiditis, autoantibodies anti-TPO and anti-Tg and right sided hemithyroidectomy were found to increase the risk of hypothyroidism post-operatively. Patients should be individually risk assessed for the development of hypothyroidism and counselled accordingly. Further research is required to explore the factors associated with transient hypothyroidism and the length of time required for recovery and to identify the factors associated with late onset hypothyroidism.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s13044-024-00200-z.

Supplementary Material 1: Supplementary Figure 1. Funnel plot for incidence of hypothyroidism following hemithyroidectomy. Supplementary Figure 2. Funnel plot for incidence of thyroxine supplementation following hemithyroidectomy. Supplementary Figure 3. Funnel plot for incidence of overt hypothyroidism following hemithyroidectomy. Supplementary Figure 4. Individual and pooled WMD for pre-operative TSH between hypothyroid and euthyroid groups following hemithyroidectomy. Supplementary Figure 5. Individual and pooled RR for pre-operative anti-TPO positivity between hypothyroid and euthyroid groups following hemithyroidectomy. Supplementary Figure 6. Individual and pooled RR for preoperative anti-Tg positivity between hypothyroid and euthyroid groups following hemithyroidectomy. Supplementary Figure 7. Individual and pooled RR for right sided hemithyroidectomy between hypothyroid and euthyroid groups following hemithyroidectomy. Supplementary Figure 8. Individual and pooled RR for malignant pathology between hypothyroid and euthyroid groups following hemithyroidectomy. Supplementary Figure 9. Individual and pooled RR of postoperative hypothyroidism for patients with a family of thyroid dysfunction. Supplementary Figure 10. Individual and pooled WMD of BMI between hypothyroid and euthyroid groups. Supplementary Figure 11. Individual and pooled WMD of remnant thyroid volume between hypothyroid and euthyroid groups. Supplementary Figure 12. Funnel plot assessing asymmetry of WMD for age between hypothyroid and euthyroid groups. Supplementary Figure 13. Funnel

plot assessing asymmetry of RR of female sex between hypothyroid and euthyroid groups. Supplementary Figure 14. Funnel plot assessing asymmetry of RR for Hashimoto's thyroiditis between hypothyroid and euthyroid groups. Supplementary Figure 15. Funnel plot assessing asymmetry of WMD of pre-operative TSH between hypothyroid and euthyroid groups. Supplementary Figure 16. Funnel plot assessing asymmetry of RR for malignant pathology between hypothyroid and euthyroid groups. Supplementary Figure 17. Funnel plot assessing asymmetry of RR for side of hemithyroidectomy between hypothyroid and euthyroid groups. Supplementary Figure 18. Funnel plot assessing asymmetry of RR for TSH \geq 2 between hypothyroid and euthyroid groups. Supplementary Figure 19. Funnel plot assessing asymmetry of RR for anti-TPO between hypothyroid and euthyroid groups. Supplementary Figure 20. Funnel plot assessing asymmetry of RR for anti-Tg between hypothyroid and euthyroid groups. Supplementary Figure 21. Funnel plot assessing asymmetry for incidence of transient hypothyroidism following hemithyroidectomy.

Supplementary Material 2.

Acknowledgements

Not applicable.

Authors' contributions

Study conception and design: D.C, S.E. Data collection: D.C, S.E. Formal analysis: D.C, R.K. Writing - original draft preparation: D.C. Writing - review and editing: FEA, GDE, S.E. Supervision- R.K, S.E.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 1 March 2024 Accepted: 12 May 2024 Published online: 08 July 2024

References

- Fewins J, Simpson CB, Miller FR. Complications of thyroid and parathyroid surgery. Otolaryngol Clin North Am. 2003;36(1):189–206. https://doi.org/ 10.1016/s0030-6665(02)00129-9.
- Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab. 2002;87:4154–9.
- Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9. https://doi.org/10.1056/NEJM20010215344 0707.
- Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 2011;342:d2238. https://doi.org/10.1136/bmj.d2238.
- Noureldine SI, Khan A, Massasati SA, et al. Thyroid hormone replacement therapy, surveillance ultrasonography, and fine-needle aspiration after hemithyroidectomy. Ann Otol Rhinol Laryngol. 2013;122(7):450–6. https://doi.org/10.1177/000348941312200707.

- Park S, Jeon MJ, Song E, et al. Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy. J Clin Endocrinol Metab. 2017;102(4):1317–24. https://doi.org/10.1210/jc.2016-3597.
- Ahn D, Sohn JH, Jeon JH. Hypothyroidism following hemithyroidectomy: Incidence, risk factors, and clinical characteristics. J Clin Endocrinol Metab. 2016;101(4):1429–36. https://doi.org/10.1210/jc.2015-3997.
- Dou Y, Chen Y, Hu D, et al. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study. Front Endocrinol. 2020;11:619841. https://doi.org/10.3389/fendo.2020. 619841.
- Stoll SJ, Pitt SC, Liu J, et al. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009;146(4):554–60. https://doi.org/10.1016/j.surg. 2009.06.026.
- Li Z, Qiu Y, Fei Y, et al. Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis. Endocrine. 2020;70(2):243–55. https://doi.org/10.1007/s12020-020-02410-5.
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–35. https://doi.org/10.1089/thy.2012.0205.
- Johner A, Griffith OL, Walker B, et al. Detection and management of hypothyroidism following thyroid lobectomy: Evaluation of a clinical algorithm. Ann Surg Oncol. 2011;18(9):2548–54. https://doi.org/10.1245/ s10434-011-1627-1.
- Buehler LA, Madhun NZ, Bena J, et al. Hormonal Outcomes Following Hemithyroidectomy. Otolaryngol Head Neck Surg. 2021;164(5):1011–8. https://doi.org/10.1177/0194599820962486.
- Kim CJ, Lee S, Bae JS, et al. Risk factors that predict levothyroxine medication after thyroid lobectomy. Acta Endocrinol (Buchar). 2020;16(4):454– 61. https://doi.org/10.5005/jp-journals-10002-1277.
- Ng P, Ho C, Tan WB, et al. Predictors of thyroxine replacement following hemithyroidectomy in a south east Asian cohort. Head Neck. 2019;41(5):1463–7. https://doi.org/10.1002/hed.25592.
- 16. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration. 2020.
- 17. Abraham CR, Ata A, Stain SC, et al. Time to Hypothyroidism Following Hemithyroidectomy. Cureus. 2022;14(12):e32837.
- Akkari M, Schmitt D, Jeandel C, et al. Nodular recurrence and hypothyroidism following partial thyroidectomy for benign nodular thyroid disease in children and adolescents. Int J Pediat Otorhinolaryngol. 2014;78(10):1742–6. https://doi.org/10.1016/j.ijporl.2014.07.037.
- Alsaleh N, Albaqmi K, Alaqel M. Effectiveness of hemi-thyroidectomy in relieving compressive symptoms in cases with large multi nodular goiter. Ann Med Surg (Lond). 2021;63:102140. https://doi.org/10.1016/j.amsu. 2021.01.088.
- Al-Shalhoub AK, Al-Dhahri S. Risk factors of post-hemithyroidectomy hypothyroidism. Saudi J Med Med Sci. 2017;5(1):45–8. https://doi.org/10. 4103/1658-631X.194243.
- Antunes CM, Taveira-Gomes A. Lobectomy in follicular thyroid neoplasms' treatment. Int J Surg. 2013;11(9):919–22. https://doi.org/10.1016/j.ijsu. 2013.07.004.
- 22. Attaallah W, Erel S, Canturk NZ, et al. Is hemithyroidectomy a rational management for benign nodular goitre? A multicentre retrospective single group study. Neth J Med. 2015;73(1):17–22.
- Balentine C, Domingo RP, Patel R, Suliburk J. Thyroid lobectomy for indeterminate FNA: not without consequence. J Surg Res. 2013;179:342.
- 24. Baran JA, Bauer AJ, Halada S, et al. Clinical Course of Early Postoperative Hypothyroidism following Thyroid Lobectomy in Pediatrics. THYROID. 2021;31(12):1786–93. https://doi.org/10.1089/thy.2021.0396.
- 25. Barczynski M, Konturek A, Golkowski F, et al. Five-year follow-up of a randomized clinical trial of unilateral thyroid lobectomy with or without postoperative levothyroxine treatment. World J Surg. 2010;34(6):1232–8. https://doi.org/10.1007/s00268-010-0439-y.
- Bauer PS, Murray S, Clark N, et al. Unilateral thyroidectomy for the treatment of benign multinodular goiter. J Surg Res. 2013;184(1):514–8. https://doi.org/10.1016/j.jss.2013.04.045.
- Beisa V, Kazanavicius D, Skrebunas A, et al. Prospective analysis of risk for hypothyroidism after hemithyroidectomy. Int J Endocrinol. 2015;2015:313971. https://doi.org/10.1155/2015/313971.

- Beisa V, Kazanavieius D, Skrebunas A, et al. Prognosis of thyroid function after hemithyroidectomya. Central Eur J Med. 2011;6(2):152–7. https:// doi.org/10.2478/s11536-010-0064-z.
- Berglund J, Aspelin P, Bondeson AG, et al. Rapid increase in volume of the remnant after hemithyroidectomy does not correlate with serum concentration of thyroid stimulating hormone. Eur J Surg Acta Chirurgica. 1998;164(4):257–62.
- Cao Z, Liu R, Wu M, et al. Risk factors for thyroid hormone replacement therapy after hemithyroidectomy and development of a predictive nomogram. Endocrine. 2022;76(1):85–94. https://doi.org/10.1007/ s12020-021-02971-z.
- Chen J, Hou S, Li X, et al. Management of subclinical and overt hypothyroidism following hemithyroidectomy in children and adolescents: A pilot study. Front Pediatr. 2019;7:396. https://doi.org/10.3389/fped.2019. 00396.
- Cheung P, Boey J, Wong J. Thyroid function after hemithyroidectomy for benign nodules. World J Surgery. 1986;10(4):718–23.
- Chidambaranathan N, Thiagarajan S, Menon N, et al. A Clinical Audit of Hemithyroidectomy for Differentiated Thyroid Cancer—Experience from a Tertiary Cancer Center. Indian J Surg. 2021. https://doi.org/10.1007/ s12262-020-02703-z.
- Cho JS, Shin SH, Song YJ, et al. Is it possible to predict hypothyroidism after thyroid lobectomy through thyrotropin, thyroglobulin, anti-thyroglobulin, and anti-microsomal antibody? J Korean Surg Soc. 2011;81(6):380–6. https://doi.org/10.4174/jkss.2011.81.6.380.
- Cho MJ, Yu HW, Kim W, et al. Comparison of the Incidence of Postoperative Hypothyroidism in Patients Undergoing Conventional Thyroid Lobectomy and Pyramid- And Isthmus-Preserving Lobectomy. Int J Endocrinol. 2021;2021:8162307. https://doi.org/10.1155/2021/8162307.
- Chong SS, Hoh SY, Huang SM. Post-hemithyroidectomy hypothyroidism in non autoimmune thyroiditis patients: Incidence, risk factors and duration of follow up. Asian J Surg. 2019;42(11):957–62. https://doi.org/10. 1016/j.asjsur.2019.01.015.
- Chotigavanich C, Sureepong P, Ongard S, et al. Hypothyroidism after hemithyroidectomy: The incidence and risk factors. J Med Assoc Thai. 2016;99(1):77–83.
- Chu KKW, Lang BHH. Clinicopathologic predictors for early and late biochemical hypothyroidism after hemithyroidectomy. Am J Surg. 2012;203(4):461–6. https://doi.org/10.1016/j.amjsurg.2011.03.004.
- De Carlucci Jr D, Tavares MR, Obara MT, et al. Thyroid function after unilateral total lobectomy: Risk factors for postoperative hypothyroidism. Arch Otolaryngology Head Neck Surg. 2008;134(10):1076–9. https://doi.org/10. 1001/archotol.134.10.1076.
- Ergul Z, Akinci M, Kulacoglu H. Hemithyroidectomy for unilateral thyroid disease. Chirurgia (Bucur). 2014;109(5):613–9.
- Ha TK, Kim DW, Park HK, et al. Factors influencing the successful maintenance of euthyroidism after lobectomy in patients with papillary thyroid microcarcinoma: A single-center study. Endoc Pract. 2019;25(10):1035–40. https://doi.org/10.4158/EP-2019-0153.
- Ito M, Miyauchi A, Kang S, et al. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol. 2015;173(3):333–40. https://doi.org/10.1530/ EJE-15-0138.
- Kim SY, Kim HJ, Kim SM, et al. Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up. Front Endocrinol (Lausanne). 2020;11:520. https://doi.org/10.3389/fendo. 2020.00520.
- Koh YW, Lee SW, Choi EC, et al. Prediction of hypothyroidism after hemithyroidectomy: A biochemical and pathological analysis. Eur Arch Otorhinolaryngol. 2008;265(4):453–7. https://doi.org/10.1007/ s00405-007-0513-8.
- Kristensen TT, Larsen J, Pedersen PL, et al. Persistent cellular metabolic changes after hemithyroidectomy for benign euthyroid goiter. Eur Thyroid J. 2014;3(1):10–6. https://doi.org/10.1159/000357943.
- Lang BH, Wong CKH, Wong KP, et al. Effect of Thyroid Remnant Volume on the Risk of Hypothyroidism After Hemithyroidectomy: A Prospective Study. Ann Surg Oncol. 2017;24(6):1525–32. https://doi.org/10.1245/ s10434-016-5743-9.
- 47. Lankarani M, Mahmoodzadeh H, Poorpezeshk N, et al. Hypothyroidism following thyroid surgery. Acta Medica Iranica. 2008;46:225–32.

- Latoo MA, Jallu AS, Batool QUA. Postoperative hypothyroidism after lobectomy for colloid goiter. Otorhinolaryngol Clin. 2020;12(2):21–4. https://doi.org/10.5005/jp-journals-10003-1354.
- Lee DY, Seok J, Jeong WJ, et al. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res. 2015;193(1):273–8. https:// doi.org/10.1016/j.jss.2014.07.003.
- Lee SJ, Song CM, Ji YB, et al. Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma. Langenbecks Arch Surg. 2021;406(4):1223–31. https://doi.org/ 10.1007/s00423-021-02189-7.
- Lindblom P, Valdemarsson S, Lindergard B, et al. Decreased levels of ionized calcium one year after hemithyroidectomy: Importance of reduced thyroid hormones. Horm Res. 2001;55(2):81–7. https://doi.org/10.1159/ 000049975.
- McHenry CR, Slusarczyk SJ. Hypothyroidisim following hemithyroidectomy: incidence, risk factors, and management. Surgery. 2000;128(6):994–8.
- Meyer CD, Anderson D, Elrod M, et al. Prediction of thyroid hormone replacement following thyroid lobectomy: A long-term retrospective study. Otolaryngol Head Neck Surg. 2020;163(1 SUPPL):P57. https://doi. org/10.1177/0194599820934780.
- Miller FR, Paulson D, Prihoda TJ, et al. Risk factors for the development of hypothyroidism after hemithyroidectomy. Arch Otolaryngol Head Neck Surg. 2006;132(1):36–8. https://doi.org/10.1001/archotol.132.1.36.
- Moon HG, Jung EJ, Park ST, et al. Thyrotropin level and thyroid volume for prediction of hypothyroidism following hemithyroidectomy in an Asian patient cohort. World J Surg. 2008;32(11):2503–8. https://doi.org/10.1007/ s00268-008-9717-3.
- Morris L, lupe I, Edeiken-Monroe B, et al. Pre-operative ultrasound identification of thyroiditis helps predict the need for thyroid hormone replacement after thyroid lobectomy. Endoc Pract. 2013;19(6):1015–20. https://doi.org/10.4158/EP12334.OR.
- Phitayakorn R, Narendra D, Bell S, et al. What Constitutes Adequate Surgical Therapy For Benign Nodular Goiter? J Surg Res. 2009;154(1):51–5. https://doi.org/10.1016/j.jss.2008.05.003.
- Piper HG, Bugis SP, Wilkins GE, et al. Detecting and defining hypothyroidism after hemithyroidectomy. Am J Surg. 2005;189(5):587–91 discussion 591.
- Rathi A. SD, Prasad B. Prediction of Hypothyroidism after Hemithyroidectomy: A Biochemical and Pathological Analysis. IOSR J Dental Med Sci. 2017;16(Issue 6):61–3.
- Said M, Chiu V, Haigh PI. Hypothyroidism after hemithyroidectomy. World journal of surgery. 2013;37(12):2839–44. https://doi.org/10.1007/ s00268-013-2201-8.
- Salih AM. Prevalence of hypothyroidism among patients with isthmuspreserved thyroid lobectomy. Journal of International Medical Research. 2018;46(9):3819–23. https://doi.org/10.1177/0300060518781228.
- Sancho JJ, Prieto R, Duenas JP, et al. A randomized trial of hemithyroidectomy versus Dunhill for the surgical management of asymmetrical multinodular goiter. Ann Surg. 2012;256(5):846–51 discussion 851-2.
- Sarkis LM, Norlen O, Sywak M, et al. Minimally invasive thyroid nodulectomy reduces post-operative hypothyroidism when compared with thyroid lobectomy. ANZ J Surg. 2017;87(5):360–3. https://doi.org/10. 1111/ans.12904.
- 64. Seiberling KA, Dutra JC, Bajaramovic S. Hypothyroidism following hemithyroidectomy for benign nontoxic thyroid disease. Ear Nose Throat J. 2007;86(5):295–9. https://doi.org/10.1177/014556130708600517.
- 65. Sellami M, Chaabouni MA, Jameleddine E, et al. Predictive factors for hypothyroidy after hemithyroidectomy. F1000Research. 2022;11:1355. https://doi.org/10.12688/f1000research.127367.2.
- Spanheimer PM, Sugg SL, Lal G, et al. Surveillance and intervention after thyroid lobectomy. Annals of Surgical Oncology. 2011;18(6):1729–33. https://doi.org/10.1245/s10434-010-1544-8.
- Su SY, Grodski S, Serpell JW. Hypothyroidism following hemithyroidectomy: A retrospective review. Ann Surg. 2009;250(6):991–4. https://doi. org/10.1097/SLA.0b013e3181ae5426.
- Tomoda C, Ito Y, Kobayashi K, et al. Subclinical hypothyroidism following hemithyroidectomy: A simple risk-scoring system using age and preoperative thyrotropin level. ORL. 2011;73(2):68–71. https://doi.org/10.1159/ 000323007.

- Vaiman M, Nagibin A, Hagag P, et al. Hypothyroidism following partial thyroidectomy. Otolaryngol Head Neck Surg. 2008;138(1):98–100. https:// doi.org/10.1016/j.otohns.2007.09.015.
- Wadström C, Zedenius J, Guinea A, et al. Multinodular goitre presenting as a clinical single nodule: How effective is hemithyroidectomy? Aust N Z J Surg. 1999;69(1):34–6. https://doi.org/10.1046/j.1440-1622.1999.01485.x.
- Wilson M, Patel A, Goldner W, et al. Postoperative thyroid hormone supplementation rates following thyroid lobectomy. Am J Surg. 2020. https:// doi.org/10.1016/j.amjsurg.2020.06.052.
- Wormald R, Sheahan P, Rowley S, et al. Hemithyroidectomy for benign thyroid disease: Who needs follow-up for hypothyroidism? Clin Otolaryngol. 2008;33(6):587–91. https://doi.org/10.1111/j.1749-4486.2008.01794.x.
- Yetkin G, Uludag M, Onceken O, et al. Does unilateral lobectomy suffice to manage unilateral nontoxic goiter? Endoc Pract. 2010;16(1):36–41. https://doi.org/10.4158/EP09140.OR.
- Ahn D, Sohn JH, Jeon JH. Hypothyroidism following hemithyroidectomy: Incidence, risk factors, and clinical characteristics. J Clin Endocrinol Metabol. 2016;101(4):1429–36. https://doi.org/10.1210/jc.2015-3997.
- Aggarwal N, Razvi S. Thyroid and aging or the aging thyroid? An evidence-based analysis of the literature. J Thyroid Res. 2013;2013:481287. https://doi.org/10.1155/2013/481287.
- Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–62. https://doi.org/10.1210/jc.2011-3020.
- Rubenstein HA, Butler VP Jr, Werner SC. Progressive decrease in serum triiodothyronine concentrations with human aging: radioimmunoassay following extraction of serum. J Clin Endocrinol Metab. 1973;37(2):247–53. https://doi.org/10.1210/jcem-37-2-247.
- Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43(1):55–68. https://doi. org/10.1111/j.1365-2265.1995.tb01894.x.
- Frohlich E, Wahl R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol. 2017;8:521. https://doi.org/10.3389/fimmu.2017.00521.
- Ragusa F, Fallahi P, Elia G, et al. Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101367. https://doi.org/10.1016/j.beem.2019.101367.
- Yildirim M, Dane S, Seven B. Morphological asymmetry in thyroid lobes, and sex and handedness differences in healthy young subjects. Int J Neurosci. 2006;116:1173–9. https://doi.org/10.1080/00207450500513997.
- Ying M, Sin MH, Pang SF. Sonographic measurement of thyroid gland volume: A comparison of 2D and 3D ultrasound. Radiography. 2005;11(4):242–24. https://doi.org/10.1016/j.radi.2005.03.010.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.